Valuation: Collegium Pharmaceutical, Inc.

Market Cap 717M 640M 596M 542M 1.02B 69.04B 1.03B 7.2B 2.8B 35.24B 2.69B 2.63B 113B P/E 2026 *
13.2x
P/E 2027 * 6.61x
Enterprise Value 1.57B 1.4B 1.3B 1.19B 2.23B 151B 2.25B 15.75B 6.13B 77.09B 5.89B 5.76B 248B EV / Sales 2026 *
1.87x
EV / Sales 2027 * 1.49x
Free-Float
77.39%
Yield 2026 *
-
Yield 2027 * -
1 week-1.01%
Current month+1.03%
1 month-5.77%
3 months-39.51%
6 months-30.05%
Current year-53.33%
1 week 19.2
Extreme 19.2
20.2
1 month 18.9
Extreme 18.9
20.8
3 years 18.9
Extreme 18.9
42.4
Manager TitleAgeSince
Chief Executive Officer 51 12/11/2024
Director of Finance/CFO 50 24/05/2021
Chief Tech/Sci/R&D Officer 65 23/03/2022
Director TitleAgeSince
Chairman 69 15/05/2025
Director/Board Member 72 01/02/2014
Director/Board Member 78 01/01/2015
Change 5-day change 1-year change 3-year change Capi.($)
-0.51%-1.01%-33.33%-9.26% 717M
+0.71%-2.61%+36.54%+113.09% 1,019B
-0.88%-6.65%+34.92%+61.55% 617B
+0.27%-1.20%+14.29%+78.43% 464B
-2.86%-5.77%+57.78%+35.24% 356B
+0.93%-1.83%+20.98%+41.43% 333B
+0.12%-4.05%+10.09%+33.53% 267B
-0.89%-5.83%-7.56%+7.91% 244B
-0.04%-3.53%+37.14%+52.17% 218B
-0.53%-5.46%+26.69%+92.63% 179B
Average -0.43%-3.54%+19.75%+50.67% 410.8B
Weighted average by Cap. -0.24%-3.54%+28.85%+68.91%

Financials

2026 *2027 *
Net sales 837M 747M 696M 633M 1.19B 80.62B 1.2B 8.41B 3.27B 41.15B 3.14B 3.07B 132B 850M 758M 707M 643M 1.21B 81.87B 1.22B 8.54B 3.32B 41.79B 3.19B 3.12B 134B
Net income 61.01M 54.43M 50.7M 46.14M 86.9M 5.88B 87.54M 613M 238M 3B 229M 224M 9.64B 130M 116M 108M 98.42M 185M 12.53B 187M 1.31B 508M 6.4B 489M 478M 20.56B
Net Debt 851M 760M 708M 644M 1.21B 81.99B 1.22B 8.55B 3.33B 41.85B 3.2B 3.13B 135B 553M 493M 460M 418M 788M 53.27B 794M 5.55B 2.16B 27.19B 2.08B 2.03B 87.39B
Logo Collegium Pharmaceutical, Inc.
Collegium Pharmaceutical, Inc. is a diversified biopharmaceutical company. The Company has developed, licensed, and acquired a portfolio of products for use in the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. Its commercial products include Jornay PM (Jornay), Belbuca, Xtampza ER (Xtampza), Nucynta ER and Nucynta IR (Nucynta Products), and Symproic in the United States. Its Jornay is a central nervous system (CNS) stimulant prescription medicine for the treatment of ADHD. The Belbuca is a buccal film that contains buprenorphine for severe and persistent pain. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. The Xtampza ER is a pain treatment option designed with abuse deterrent properties. Its portfolio also includes AZSTARYS (serdexmethylphenidate and dexmethylphenidate), a central nervous system (CNS) stimulant prescription medicine used for the treatment of ADHD in people six years of age and older.
Employees
-
Date Price Change
05/10/26 €19.50 -0.51%
02/10/26 €19.60 +0.51%
01/10/26 €19.50 +0.52%
30/09/26 €19.40 0.00%
29/09/26 €19.40 -2.51%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
22.02USD
Average target price
49.00USD
Spread / Average Target
+122.52%

Quarterly revenue - Rate of surprise